Significance/NN
of/IN
quantitative/JJ
analysis/NN
of/IN
AML1/ETO/NN
transcripts/NNS
in/IN
peripheral/JJ
blood/NN
stem/NN
cells/NNS
from/IN
t(8;21)/NN
acute/JJ
myelogenous/JJ
leukemia/NN
./.

Autologous/JJ
peripheral/JJ
blood/NN
stem/NN
cell/NN
transplantation/NN
(/(
PBSCT/NN
)/)
is/VBZ
replacing/VBG
autologous/JJ
bone/NN
marrow/NN
transplantation/NN
(/(
BMT/NN
)/)
in/IN
the/DT
treatment/NN
of/IN
leukemia/NN
./.
=====
One/CD
of/IN
the/DT
potential/JJ
advantages/NNS
of/IN
autologous/JJ
PBSCT/NN
is/VBZ
the/DT
possibility/NN
that/IN
peripheral/JJ
blood/NN
stem/NN
cells/NNS
(/(
PBSC/NNS
)/)
are/VBP
less/RBR
likely/JJ
to/TO
be/VB
contaminated/VBN
by/IN
leukemic/JJ
cells/NNS
than/IN
bone/NN
marrow/NN
grafts/NNS
./.
=====
However/RB
,/,
the/DT
major/JJ
problem/NN
still/RB
remains/VBZ
the/DT
high/JJ
incidence/NN
of/IN
leukemic/JJ
relapse/NN
following/VBG
autologous/JJ
PBSCT/NN
,/,
which/WDT
may/MD
be/VB
caused/VBN
by/IN
the/DT
reinfusion/NN
of/IN
PBSC/NNS
contaminated/VBN
by/IN
leukemic/JJ
cells/NNS
./.
=====
Recently/RB
,/,
we/PRP
have/VBP
developed/VBN
a/DT
quantitative/JJ
assay/NN
using/VBG
competitive/JJ
reverse/JJ
transcriptase/NN
polymerase/NN
chain/NN
reaction/NN
that/WDT
estimates/VBZ
the/DT
number/NN
of/IN
AML1/ETO/NN
transcripts/NNS
in/IN
t(8;21)/NN
acute/JJ
myelogenous/JJ
leukemia/NN
(/(
AML/NN
)/)
,/,
in/IN
order/NN
to/TO
determine/VB
the/DT
degree/NN
of/IN
leukemic/JJ
cell/NN
contamination/NN
in/IN
PBSC/NNS
harvests/NNS
,/,
and/CC
to/TO
monitor/VB
minimal/JJ
residual/JJ
disease/NN
(/(
MRD/NN
)/)
quantitatively/RB
in/IN
patients/NNS
with/IN
t(8;21)/NN
AML/NN
./.
=====
Our/PRP$
data/NNS
indicate/VBP
that/IN
although/IN
PBSC/NNS
harvests/NNS
collected/VBN
after/IN
consolidation/NN
chemotherapy/NN
are/VBP
contaminated/VBN
by/IN
leukemic/JJ
cells/NNS
,/,
the/DT
degree/NN
of/IN
leukemic/JJ
cell/NN
contamination/NN
decreases/VBZ
with/IN
repeated/JJ
cycles/NNS
of/IN
chemotherapy/NN
./.
=====
Furthermore/RB
,/,
the/DT
MRD/NN
in/IN
PBSC/NNS
harvests/NNS
is/VBZ
less/JJR
than/IN
in/IN
the/DT
corresponding/JJ
bone/NN
marrow/NN
obtained/VBN
on/IN
the/DT
day/NN
of/IN
the/DT
PBSC/NNS
collection/NN
./.
=====
There/EX
appears/VBZ
to/TO
be/VB
no/DT
relationship/NN
between/IN
the/DT
number/NN
of/IN
AML1/ETO/NN
transcripts/NNS
found/VBN
in/IN
the/DT
infused/VBN
PBSC/NNS
harvests/NNS
and/CC
the/DT
incidence/NN
of/IN
leukemic/JJ
relapse/NN
following/VBG
autologous/JJ
PBSCT/NNS
in/IN
our/PRP$
study/NN
./.
=====
However/RB
,/,
a/DT
substantial/JJ
decrease/NN
of/IN
AML1/ETO/NN
transcripts/NNS
was/VBD
seen/VBN
following/VBG
autologous/JJ
PBSCT/NNS
./.
=====
Thus/RB
,/,
the/DT
quantitative/JJ
analysis/NN
of/IN
AML1/ETO/NN
transcripts/NNS
may/MD
be/VB
clinically/RB
useful/JJ
in/IN
patients/NNS
with/IN
t(8;21)/NN
AML/NN
./.